The cardioprotective effects of hydrogen sulfide in heart diseases: From molecular mechanisms to therapeutic potential

Oxidative Medicine and Cellular Longevity

Volumn 2015, Issue , 2015, Pages

  Shen, Yaqi ^a   Shen, Zhuqing ^a   Luo, Shanshan ^a   Guo, Wei ^a   Zhu, Yi Zhun ^a,b  

^a FUDAN UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CARBON; CARBON MONOXIDE; CARDIOLOGY; CELL DEATH; DISEASES; HEART; MAMMALS; NITRIC OXIDE; SULFUR DETERMINATION;

ANTI-INFLAMMATORY RESPONSE; CARDIOPROTECTIVE EFFECT; ISCHEMIA-REPERFUSION INJURY; MITOCHONDRIAL FUNCTION; MYOCARDIAL INFARCTION; PATHOLOGICAL PROCESS; THERAPEUTIC POTENTIALS; THERAPEUTIC TARGETS;

HYDROGEN SULFIDE;

HYDROGEN SULFIDE; ION CHANNEL; MICRORNA; NITRIC OXIDE; PROTECTIVE AGENT;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; DIABETIC CARDIOMYOPATHY; DRUG MECHANISM; DRUG METABOLISM; DRUG SYNTHESIS; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART HYPERTROPHY; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; INFLAMMATION; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; ANIMAL; DRUG EFFECTS; HEART DISEASES; METABOLISM; MITOCHONDRION; PATHOLOGY; SIGNAL TRANSDUCTION;

MAMMALIA;

ANIMALS; HEART DISEASES; HEART FAILURE; HYDROGEN SULFIDE; MITOCHONDRIA; NITRIC OXIDE; PROTECTIVE AGENTS; SIGNAL TRANSDUCTION;

EID: 84930666218     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2015/925167     Document Type: Review

References (130)

1. K. Abe and H. Kimura, "Thepossible role of hydrogen sulfide as an endogenous neuromodulator", The Journal of Neuroscience, vol. 16, no. 3, pp. 1066-1071, 1996.
2. 2S be the third endogenous gaseous transmitter?" The FASEB Journal, vol. 16, no. 13, pp. 1792-1798, 2002.
3. R. Wang, "Physiological implications of hydrogen sulfide: a whiff exploration that blossomed", Physiological Reviews, vol. 92, no. 2, pp. 791-896, 2012.
4. H. Liu, X.-B. Bai, S. Shi, and Y.-X. Cao, "Hydrogen sulfide protects from intestinal ischaemia-reperfusion injury in rats", Journal of Pharmacy and Pharmacology, vol. 61, no. 2, pp. 207-212, 2009.
5. F. Wagner, P. Asfar, E. Calzia, P. Radermacher, and C. Szabó, "Bench-to-bedside review: hydrogen sulfide-the third gaseous transmitter: applications for critical care", Critical Care, vol. 13, no. 3, p. 213, 2009.
6. N. Shibuya, M. Tanaka, M. Yoshida et al., "3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain", Antioxidants and Redox Signaling, vol. 11, no. 4, pp. 703-714, 2009.
7. 2S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine γ-lyase", Science, vol. 322, no. 5901, pp. 587-590, 2008.
8. C. Yang, Z. Yang, M. Zhang et al., "Hydrogen sulfide protects against chemical hypoxia-induced cytotoxicity and inflammation in hacat cells through inhibition of ROS/NF-κB/COX-2 pathway", PLoS ONE, vol. 6, no. 7, Article ID e21971, 2011.
9. Y. Kaneko, Y. Kimura, H. Kimura, and I. Niki, "l-cysteine inhibits insulin release from the pancreatic α-cell: possible involvement of metabolic production of hydrogen sulfide, a novel gasotransmitter", Diabetes, vol. 55, no. 5, pp. 1391-1397, 2006.
10. P. Patel, M. Vatish, J. Heptinstall, R. Wang, and R. J. Carson, "The endogenous production of hydrogen sulphide in intrauterine tissues", Reproductive Biology and Endocrinology, vol. 7, article 10, 2009.
11. M. H. Stipanuk and P. W. Beck, "Characterization of the enzymic capacity for cysteine desulphhydration in liver and kidney of the rat", Biochemical Journal, vol. 206, no. 2, pp. 267-277, 1982.
12. R. Hosoki, N. Matsuki, and H. Kimura, "The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide", Biochemical and Biophysical Research Communications, vol. 237, no. 3, pp. 527-531, 1997.
13. 2S in rat insulin-secreting cells and the underlying mechanisms", The Journal of Physiology, vol. 569, no. 2, pp. 519-531, 2005.
14. Y. Mikami, N. Shibuya, Y. Kimura, N. Nagahara, Y. Ogasawara, and H. Kimura, "Thioredoxin and dihydrolipoic acid are required for 3-mercaptopyruvate sulfurtransferase to produce hydrogen sulfide", Biochemical Journal, vol. 439, no. 3, pp. 479-485, 2011.
15. Y. Mikami, N. Shibuya, Y. Kimura, N. Nagahara, M. Yamada, and H. Kimura, "Hydrogen sulfide protects the retina from light-induced degeneration by the modulation of Ca2+ influx", The Journal of Biological Chemistry, vol. 286, no. 45, pp. 39379-39386, 2011.
16. N. Shibuya, Y. Mikami, Y. Kimura, N. Nagahara, and H. Kimura, "Vascular endothelium expresses 3-mercaptopyruvate sulfurtransferase and produces hydrogen sulfide", The Journal of Biochemistry, vol. 146, no. 5, pp. 623-626, 2009.
17. N. Shibuya, M. Tanaka, M. Yoshida et al., "3-Mercaptopyruvate sulfurtransferase produces hydrogen sulfide and bound sulfane sulfur in the brain", Antioxidants and Redox Signaling, vol. 11, no. 4, pp. 703-714, 2009.
18. L. Li, P. Rose, and P. K. Moore, "Hydrogen sulfide and cell signaling", Annual Review of Pharmacology and Toxicology, vol. 51, pp. 169-187, 2011.
19. M. Lavu, S. Bhushan, and D. J. Lefer, "Hydrogen sulfide-mediated cardioprotection: mechanisms and therapeutic potential", Clinical Science, vol. 120, no. 6, pp. 219-229, 2011.
20. N. Shibuya, S. Koike, M. Tanaka et al., "A novel pathway for the production of hydrogen sulfide fromD-cysteine in mammalian cells", Nature Communications, vol. 4, article 1366, 2013.
21. H. Kimura, "Metabolic turnover of hydrogen sulfide", Frontiers in Physiology, vol. 3, article 101, 2012.
22. H. Kimura, "Physiological role of hydrogen sulfide and polysulfide in the central nervous system", Neurochemistry International, vol. 63, no. 5, pp. 492-497, 2013.
23. T. C. Bartholomew, G. M. Powell, K. S. Dodgson, and C. G. Curtis, "Oxidation of sodium sulphide by rat liver, lungs and kidney", Biochemical Pharmacology, vol. 29, no. 18, pp. 2431-2437, 1980.
24. 2S in patients with coronary heart disease", Academic Journal of the First Medical College of PLA, vol. 25, no. 8, pp. 951-954, 2005.
25. D. J. Polhemus, J. W. Calvert, J. Butler, and D. J. Lefer, "The cardioprotective actions of hydrogen sulfide in acute myocardial infarction and heart failure", Scientifica, vol. 2014, Article ID 768607, 8 pages, 2014.
26. Y. H. Liu, M. Lu, L. F. Hu, P. T. H. Wong, G. D. Webb, and J. S. Bian, "Hydrogen sulfide in the mammalian cardiovascular system", Antioxidants & Redox Signaling, vol. 17, no. 1, pp. 141-185, 2012.
27. N. S. Dhalla, A. B. Elmoselhi, T. Hata, and N. Makino, "Status of myocardial antioxidants in ischemia-reperfusion injury", Cardiovascular Research, vol. 47, no. 3, pp. 446-456, 2000.
28. H.-F. Luan, Z.-B. Zhao, Q.-H. Zhao, P. Zhu, M.-Y. Xiu, and Y. Ji, "Hydrogen sulfide postconditioning protects isolated rat hearts against ischemia and reperfusion injury mediated by the JAK2/STAT3 survival pathway", Brazilian Journal of Medical and Biological Research, vol. 45, no. 10, pp. 898-905, 2012.
29. H. F. Jin, Y. Wang, X. B. Wang, Y. Sun, C. S. Tang, and J. B. Du, "Sulfur dioxide preconditioning increases antioxidative capacity in rat with myocardial ischemia reperfusion (I/R) injury", Nitric Oxide: Biology and Chemistry, vol. 32, pp. 56-61, 2013.
30. R. M. Osipov, M. P. Robich, J. Feng et al., "Effect of hydrogen sulfide in a porcine model of myocardial ischemia-reperfusion: comparison of different administration regimens and characterization of the cellular mechanisms of protection", Journal of Cardiovascular Pharmacology, vol. 54, no. 4, pp. 287-297, 2009.
31. T. V. Shymans'ka, I. V. Hoshovs'ka, O. M. Semenikhina, and V. F. Sahach, "Effect of hydrogen sulfideonisolatedrat heart reaction under volume load and ischemia-reperfusion", FiziolohichnyѤ Zhurnal, vol. 58, no. 6, pp. 57-66, 2012.
32. Y. Zhuo, P. F. Chen, A. Z. Zhang, H. Zhong, C. Q. Chen, and Y. Z. Zhu, "Cardioprotective effect of hydrogen sulfide in ischemic reperfusion experimental rats and its influence on expression of survivin gene", Biological and Pharmaceutical Bulletin, vol. 32, no. 8, pp. 1406-1410, 2009.
33. J. W. Elrod, J. W. Calvert, J. Morrison et al., "Hydrogen sulfide attenuates myocardial ischemia-reperfusion injury by preservation of mitochondrial function", Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 39, pp. 15560-15565, 2007.
34. G. Olivetti, F. Quaini, R. Sala et al., "Acute myocardial infarction in humans is associated with activation of programmed myocyte cell death in the surviving portion of the heart", Journal of Molecular and Cellular Cardiology, vol. 28, no. 9, pp. 2005-2016, 1996.
35. P. Anversa, W. Cheng, Y. Liu, A. Leri, G. Redaelli, and J. Kajstura, "Apoptosis and myocardial infarction", Basic Research in Cardiology, vol. 93, no. 3, supplement, pp. 8-12, 1998.
36. Y. Z. Zhu, J. W. Zhong, P. Ho et al., "Hydrogen sulfide and its possible roles in myocardial ischemia in experimental rats", Journal of Applied Physiology, vol. 102, no. 1, pp. 261-268, 2007.
37. 2S production", Antioxidants & Redox Signaling, vol. 12, no. 10, pp. 1155-1165, 2010.
38. Y. Shen, Z. Shen, L. Miao et al., "MiRNA-30 family inhibition protects against cardiac ischemic injury by regulating cystathionine-gamma-lyase expression", Antioxidants & Redox Signaling, 2014.
39. N. Qipshidze, N. Metreveli, P. K. Mishra, D. Lominadze, and S. C. Tyagi, "Hydrogen sulfide mitigates cardiac remodeling duringmyocardial infarction via improvement of angiogenesis", International Journal of Biological Sciences, vol. 8, no. 4, pp. 430-441, 2012.
40. X. Xie, A. Sun, W. Zhu et al., "Transplantation of mesenchymal stem cells preconditioned with hydrogen sulfide enhances repair of myocardial infarction in rats", The Tohoku Journal of Experimental Medicine, vol. 226, no. 1, pp. 29-36, 2012.
41. K. Pourkhalili, S. Hajizadeh, T. Tiraihi et al., "Ischemia and reperfusion-induced arrhythmias: role of hyperoxic preconditioning", Journal of Cardiovascular Medicine, vol. 10, no. 8, pp. 635-642, 2009.
42. Z. Zhang, H. Huang, P. Liu, C. Tang, and J. Wang, "Hydrogen sulfide contributes to cardioprotection during ischemia-reperfusion injury by opening KATP channels", Canadian Journal of Physiology and Pharmacology, vol. 85, no. 12, pp. 1248-1253, 2007.
43. J.-S. Bian, Q. C. Yong, T.-T. Pan et al., "Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes", The Journal of Pharmacology and Experimental Therapeutics, vol. 316, no. 2, pp. 670-678, 2006.
44. W. Roell, T. Lewalter, P. Sasse et al., "Engraftment of connexin 43-expressing cells prevents post-infarct arrhythmia", Nature, vol. 450, no. 7171, pp. 819-824, 2007.
45. J. L. Huang, D. M. Wang, J. B. Zheng, X. S. Huang, and H. Jin, "Hydrogen sulfide attenuates cardiac hypertrophy and fibrosis induced by abdominal aortic coarctation in rats", Molecular Medicine Reports, vol. 5, no. 4, pp. 923-928, 2012.
46. Q. C. Yong, T.-T. Pan, L.-F. Hu, and J.-S. Bian, "Negative regulation of β-adrenergic function by hydrogen sulphide in the rat hearts", Journal of Molecular and Cellular Cardiology, vol. 44, no. 4, pp. 701-710, 2008.
47. G.-M. Qi, L.-X. Jia, Y.-L. Li, H.-H. Li, and J. Du, "Adiponectin suppresses angiotensin II-induced inflammation and cardiac fibrosis through activation of macrophage autophagy", Endocrinology, vol. 155, no. 6, pp. 2254-2265, 2014.
48. P. Camelliti, T. K. Borg, and P. Kohl, "Structural and functional characterisation of cardiac fibroblasts", Cardiovascular Research, vol. 65, no. 1, pp. 40-51, 2005.
49. 2S ameliorates oxidative and proteolytic stresses and protects the heart against adverse remodeling in chronic heart failure", American Journal of Physiology. Heart and Circulatory Physiology, vol. 298, no. 2, pp. H451-H456, 2010.
50. G.-R. Li, H.-Y. Sun, J.-B. Chen, Y. Zhou, H.-F. Tse, and C.-P. Lau, "Characterization of multiple ion channels in cultured human cardiac fibroblasts", PLoS ONE, vol. 4, no. 10, Article ID e7307, 2009.
51. J. Sheng, W. Shim, H. Wei et al., "Hydrogen sulphide suppresses human atrial fibroblast proliferation and transformation to myofibroblasts", Journal of Cellular and Molecular Medicine, vol. 17, no. 10, pp. 1345-1354, 2013.
52. X. Wang, Q. Wang, W. Guo, and Y. Z. Zhu, "Hydrogen sulfide attenuates cardiac dysfunction in a rat model of heart failure: a mechanism through cardiac mitochondrial protection", Bioscience Reports, vol. 31, no. 2, pp. 87-98, 2011.
53. L.-L. Pan, X.-H. Liu, Y.-Q. Shen et al., "Inhibition of NADPH oxidase 4-related signaling by sodium hydrosulfide attenuates myocardial fibrotic response", International Journal of Cardiology, vol. 168, no. 4, pp. 3770-3778, 2013.
54. C. Indolfi, E. Di Lorenzo, C. Perrino et al., "Hydroxymethylglutaryl coenzyme a reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation", Circulation, vol. 106, no. 16, pp. 2118-2124, 2002.
55. F. Lu, J. Xing, X. Zhang et al., "Exogenous hydrogen sulfide prevents cardiomyocyte apoptosis from cardiac hypertrophy induced by isoproterenol", Molecular and Cellular Biochemistry, vol. 381, no. 1-2, pp. 41-50, 2013.
56. C. K. Nicholson, J. P. Lambert, J. D. Molkentin, J. Sadoshima, and J. W. Calvert, "Thioredoxin 1 is essential for sodium sulfidemediated cardioprotection in the setting of heart failure", Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 4, pp. 744-751, 2013.
57. F. Yang, Z. Liu, Y. Wang, Z. Li, H. Yu, and Q. Wang, "Hydrogen sulfide endothelin-induced myocardial hypertrophy in rats and themechanism involved", Cell Biochemistry and Biophysics, vol. 70, no. 3, pp. 1683-1686, 2014.
58. J. Huang, D. Wang, J. Zheng, X. Huang, and H. Jin, "Hydrogen sulfide attenuates cardiac hypertrophy and fibrosis induced by abdominal aortic coarctation in rats", Molecular Medicine Reports, vol. 5, no. 4, pp. 923-928, 2012.
59. R. Padiya, D. Chowdhury, R. Borkar, R. Srinivas, M. P. Bhadra, and S. K. Banerjee, "Garlic attenuates cardiac oxidative stress via activation of PI3K/AKT/Nrf2-Keap1 pathway in fructosefed diabetic rat", PLoS ONE, vol. 9, no. 5, Article IDe94228, 2014.
60. J. W. Calvert, M. Elston, C. K. Nicholson et al., "Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemiainduced heart failure in mice", Circulation, vol. 122, no. 1, pp. 11-19, 2010.
61. 2S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase", Circulation, vol. 127, no. 10, pp. 1116-1127, 2013.
62. K. Kondo, S. Bhushan, M. E. Condit, A. L. King, B. L. Predmore, and D. J. Lefer, "Hydrogen sulfide attenuates cardiac dysfunction following pressure overload induced hypertrophy and heart failure via augmentation of angiogenesis", Circulation, vol. 124, no. 21, 2011.
63. D. J. Polhemus, K. Kondo, S. Bhushan et al., "Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis", Circulation: Heart Failure, vol. 6, no. 5, pp. 1077-1086, 2013.
64. S. Givvimani, S. Kundu, N. Narayanan et al., "TIMP-2 mutant decreases MMP-2 activity and augments pressure overload induced LV dysfunction and heart failure", Archives of Physiology and Biochemistry, vol. 119, no. 2, pp. 65-74, 2013.
65. C. Y. Zhang, X. H. Li, T. Zhang, J. Fu, and X. D. Cui, "Hydrogen sulfide upregulates heme oxygenase-1 expression in rats with volume overload-induced heart failure", Biomedical Reports, vol. 1, no. 3, pp. 454-458, 2013.
66. Y.-H. Liu, M. Lu, Z.-Z. Xie et al., "Hydrogen sulfide prevents heart failure development via inhibition of renin release from mast cells in isoproterenol-treated rats", Antioxidants & Redox Signaling, vol. 20, no. 5, pp. 759-769, 2014.
67. C. Huang, J. Kan, X. Liu et al., "Cardioprotective effects of a novel hydrogen sulfide agent-controlled release formulation of S-propargyl-cysteine on heart failure rats and molecular mechanisms", PLoS ONE, vol. 8, no. 7, Article ID e69205, 2013.
68. J. T. Kan, W. Guo, C. R. Huang, G. Z. Bao, Y. C. Zhu, and Y. Z. Zhu, "S-propargyl-cysteine, a novel water-soluble modulator of endogenous hydrogen sulfide, promotes angiogenesis through activation of signal transducer and activator of transcription 3", Antioxidants & Redox Signaling, vol. 20, no. 15, pp. 2303-2316, 2014.
69. O. Asghar, A. Al-Sunni, K. Khavandi et al., "Diabetic cardiomyopathy", Clinical Science, vol. 116, no. 10, pp. 741-760, 2009.
70. 2S synthesis in streptozotocin induced Type-2 diabetesan experimental study based on Swietenia macrophylla seeds", Asian Pacific Journal of Tropical Biomedicine, vol. 4, supplement 1, pp. S483-S487, 2014.
71. S. K. Jain, R. Bull, J. L. Rains et al., "Low levels of hydrogen sulfide in the blood of diabetes patients and streptozotocintreated rats causes vascular inflammation?" Antioxidants & Redox Signaling, vol. 12, no. 11, pp. 1333-1337, 2010.
72. W. Xu, W. Wu, J. Chen et al., "Exogenous hydrogen sulfide protects H9c2 cardiac cells against high glucose-induced injury by inhibiting the activities of the p38 MAPK and ERK1/2 pathways", International Journal of Molecular Medicine, vol. 32, no. 4, pp. 917-925, 2013.
73. W.-B. Wei, X. Hu, X.-D. Zhuang, L.-Z. Liao, and W.-D. Li, "GYY4137, a novel hydrogen sulfide-releasing molecule, likely protects against high glucose-induced cytotoxicity by activation of the AMPK/mTOR signal pathway in H9c2 cells", Molecular and Cellular Biochemistry, vol. 389, no. 1-2, pp. 249-256, 2014.
74. X. Zhou, G. An, and X. Lu, "Hydrogen sulfide attenuates the development of diabetic cardiomyopathy", Clinical Science, vol. 128, no. 5, pp. 325-335, 2015.
75. B. F. Peake, C. K. Nicholson, J. P. Lambert et al., "Hydrogen sulfide preconditions the db/db diabetic mouse heart against ischemia-reperfusion injury by activating Nrf2 signaling in an Erk-dependent manner", The American Journal of Physiology-Heart and Circulatory Physiology, vol. 304, no. 9, pp. H1215-H1224, 2013.
76. W.-H. Sun, F. Liu, Y. Chen, and Y.-C. Zhu, "Hydrogen sulfide decreases the levels of ROS by inhibiting mitochondrial complex IV and increasing SOD activities in cardiomyocytes under ischemia/reperfusion", Biochemical and Biophysical Research Communications, vol. 421, no. 2, pp. 164-169, 2012.
77. C. Szabõ, "Hydrogen sulphide and its therapeutic potential", Nature Reviews Drug Discovery, vol. 6, no. 11, pp. 917-935, 2007.
78. J. W. Calvert, W. A. Coetzee, and D. J. Lefer, "Novel insights into hydrogen sulfide-mediated cytoprotection", Antioxidants & Redox Signaling, vol. 12, no. 10, pp. 1203-1217, 2010.
79. 2S preconditioning-induced PKC activation regulates intracellular calcium handling in rat cardiomyocytes", The American Journal of Physiology-Cell Physiology, vol. 294, no. 1, pp. C169-C177, 2008.
80. M. K. Muellner, S. M. Schreier, H. Laggner et al., "Hydrogen sulfide destroys lipid hydroperoxides in oxidized LDL", Biochemical Journal, vol. 420, no. 2, pp. 277-281, 2009.
81. M. Marí, A. Morales, A. Colell, C. García-Ruiz, and J. C. Fernández-Checa, "Mitochondrial glutathione, a key survival antioxidant", Antioxidants & Redox Signaling, vol. 11, no. 11, pp. 2685-2700, 2009.
82. M. G. Alves, A. F. Soares, R. A. Carvalho, and P. J. Oliveira, "Sodium hydrosulfide improves the protective potential of the cardioplegic histidine buffer solution", European Journal of Pharmacology, vol. 654, no. 1, pp. 60-67, 2011.
83. M. A. Aon, S. Cortassa, F. G. Akar, and B. O'Rourke, "Mitochondrial criticality: a new concept at the turning point of life or death", Biochimica et Biophysica Acta-Molecular Basis of Disease, vol. 1762, no. 2, pp. 232-240, 2006.
84. E. N. Churchill and D. Mochly-Rosen, "The roles of PKCδ and ε isoenzymes in the regulation of myocardial ischaemia/reperfusion injury", Biochemical Society Transactions, vol. 35, no. 5, pp. 1040-1042, 2007.
85. E. Murphy and C. Steenbergen, "Preconditioning: the mitochondrial connection", Annual Review of Physiology, vol. 69, pp. 51-67, 2007.
86. X. Zhou and X. Lu, "Hydrogen sulfide inhibits high-glucoseinduced apoptosis in neonatal rat cardiomyocytes", Experimental Biology and Medicine, vol. 238, no. 4, pp. 370-374, 2013.
87. N. R. Sodha, R. T. Clements, J. Feng et al., "The effects of therapeutic sulfide on myocardial apoptosis in response to ischemia-reperfusion injury", European Journal of Cardio-Thoracic Surgery, vol. 33, no. 5, pp. 906-913, 2008.
88. L.-L. Yao, X.-W. Huang, Y.-G. Wang, Y.-X. Cao, C.-C. Zhang, and Y.-C. Zhu, "Hydrogen sulfide protects cardiomyocytes from hypoxia/reoxygenation-induced apoptosis by preventing GSK-3β-dependent opening of mPTP", American Journal of Physiology-Heart and Circulatory Physiology, vol. 298, no. 5, pp. H1310-H1319, 2010.
89. B. J. Pomerantz, L. L. Reznikov, A. H. Harken, and C. A. Dinarello, "Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1 beta", Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2871-2876, 2001.
90. H. A. Hennein, H. Ebba, J. L. Rodriguez et al., "Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization", Journal of Thoracic and Cardiovascular Surgery, vol. 108, no. 4, pp. 626-635, 1994.
91. C. A. Dinarello, "Proinflammatory cytokines", Chest, vol. 118, no. 2, pp. 503-508, 2000.
92. M. Whiteman and P. G. Winyard, "Hydrogen sulfide and inflammation: the good, the bad, the ugly and the promising", Expert Review of Clinical Pharmacology, vol. 4, no. 1, pp. 13-32, 2011.
93. N. R. Sodha, R. T. Clements, J. Feng et al., "Hydrogen sulfide therapy attenuates the inflammatory response in a porcine model of myocardial ischemia/reperfusion injury", The Journal of Thoracic and Cardiovascular Surgery, vol. 138, no. 4, pp. 977-984, 2009.
94. R. C. O. Zanardo, V. Brancaleone, E. Distrutti, S. Fiorucci, G. Cirino, and J. L. Wallace, "Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation", The FASEB Journal, vol. 20, no. 12, pp. 2118-2120, 2006.
95. L.-L. Pan, X.-H. Liu, Q.-H. Gong, and Y.-Z. Zhu, "S-Propargylcysteine (SPRC) attenuated lipopolysaccharide-induced inflammatory response in H9c2 cells involved in a hydrogen sulfidedependent mechanism", Amino Acids, vol. 41, no. 1, pp. 205-215, 2011.
96. C. Szabó and A. Papapetropoulos, "Hydrogen sulphide and angiogenesis: mechanisms and applications", British Journal of Pharmacology, vol. 164, no. 3, pp. 853-865, 2011.
97. A. Papapetropoulos, A. Pyriochou, Z. Altaany et al., "Hydrogen sulfide is an endogenous stimulator of angiogenesis", Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 51, pp. 21972-21977, 2009.
98. S. Givvimani, C. Munjal, R. Gargoum et al., "Hydrogen sulfide mitigates transition from compensatory hypertrophy to heart failure", Journal of Applied Physiology, vol. 110, no. 4, pp. 1093-1100, 2011.
99. ATP channel opener", The EMBO Journal, vol. 20, no. 21, pp. 6008-6016, 2001.
100. S. Kai, T. Tanaka, H. Daijo et al., "Hydrogen sulfide inhibits hypoxia-but not anoxia-induced hypoxia-inducible factor 1 activation in a von hippel-lindau-andmitochondria-dependent manner", Antioxidants and Redox Signaling, vol. 16, no. 3, pp. 203-216, 2012.
101. 2S-targeting receptor protein kinase with its novel Cys1045-Cys1024 disulfide bond serving as a specific molecular switch for hydrogen sulfide actions in vascular endothelial cells", Antioxidants & Redox Signaling, vol. 19, no. 5, pp. 448-464, 2013.
102. D. M. Bers, "Calcium cycling and signaling in cardiac myocytes", Annual Review of Physiology, vol. 70, pp. 23-49, 2008.
103. G. H. Tang, L. Y. Wu, and R. Wang, "Interaction of hydrogen sulfide with ion channels", Clinical and Experimental Pharmacology and Physiology, vol. 37, no. 7, pp. 753-763, 2010.
104. Y. G. Sun, Y. X. Cao, W. W. Wang, S. F. Ma, T. Yao, and Y. C. Zhu, "Hydrogen sulphide is an inhibitor of L-type calcium channels and mechanical contraction in rat cardiomyocytes", Cardiovascular Research, vol. 79, no. 4, pp. 632-641, 2008.
105. R. Y. Zhang, Y. Sun, H. J. Tsai, C. S. Tang, H. F. Jin, and J. B. Du, "Hydrogen sulfide inhibits L-type calcium currents depending upon the protein sulfhydryl state in rat cardiomyocytes", PLoS ONE, vol. 7, no. 5, Article ID e37073, 2012.
106. G. Vassort, K. Talavera, and J. L. Alvarez, "Role of T-type Ca2+ channels in the heart", Cell Calcium, vol. 40, no. 2, pp. 205-220, 2006.
107. J. Elies, J. L. Scragg, S. Huang et al., "Hydrogen sulfide inhibits Cav3.2 T-type Ca2+ channels", The FASEB Journal, vol. 28, no. 12, pp. 5376-5387, 2014.
108. ATP channels by exogenous and endogenous hydrogen sulfide in vascular smooth muscle cells", Molecular Pharmacology, vol. 68, no. 6, pp. 1757-1764, 2005.
109. S. W. Lee, Y. Cheng, P. K. Moore, and J. S. Bian, "Hydrogen sulphide regulates intracellular pH in vascular smooth muscle cells", Biochemical and Biophysical Research Communications, vol. 358, no. 4, pp. 1142-1147, 2007.
110. ATP channels", Basic Research in Cardiology, vol. 101, no. 1, pp. 53-60, 2006.
111. ATP channels", Canadian Journal of Physiology and Pharmacology, vol. 85, no. 12, pp. 1248-1253, 2007.
112. ν1.5", The American Journal of Physiology. Gastrointestinal and Liver Physiology, vol. 300, no. 6, pp. G1105-G1114, 2011.
113. 2S and HS. donor NaHS inhibits intracellular chloride channels", General Physiology and Biophysics, vol. 28, no. 2, pp. 190-194, 2009.
114. A. L. King, D. J. Polhemus, S. Bhushan et al., "Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthasenitric oxide dependent", Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 8, pp. 3182-3187, 2014.
115. M. Whiteman, L. Li, I. Kostetski et al., "Evidence for the formation of a novel nitrosothiol from the gaseous mediators nitric oxide and hydrogen sulphide", Biochemical and Biophysical Research Communications, vol. 343, no. 1, pp. 303-310, 2006.
116. B. L. Predmore, K. Kondo, S. Bhushan et al., "The polysulfide diallyl trisulfide protects the ischemicmyocardiumby preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability", The American Journal of Physiology. Heart and Circulatory Physiology, vol. 302, no. 11, pp. H2410-H2418, 2012.
117. E. Owicka and J. Betowski, "Hydrogen sulfide (H2S).the third gas of interest for pharmacologists", Pharmacological Reports, vol. 59, no. 1, pp. 4-24, 2007.
118. J. Fiedler, S. Batkai, and T. Thum, "MicroRNA-based therapy in cardiology", Herz, vol. 39, no. 2, pp. 194-200, 2014.
119. J. Shen, T. Xing, H. Yuan et al., "Hydrogen sulfide improves drought tolerance in Arabidopsis thaliana bymicroRNAexpressions", PLoS ONE, vol. 8, no. 10, Article IDe77047, 2013.
120. X. Huang, Y. Gao, J. Qin, and S. Lu, "The role of miR-34a in the hepatoprotective effect of hydrogen sulfide on ischemia/reperfusion injury in young and old rats", PLoS ONE, vol. 9, no. 11, Article ID e113305, 2014.
121. J. Liu, D.-D. Hao, J.-S. Zhang, and Y.-C. Zhu, "Hydrogen sulphide inhibits cardiomyocyte hypertrophy by up-regulating miR-133a", Biochemical and Biophysical Research Communications, vol. 413, no. 2, pp. 342-347, 2011.
122. S. Toldo, A. Das, E. Mezzaroma et al., "Induction ofmicroRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice", Circulation: Cardiovascular Genetics, vol. 7, no. 3, pp. 311-320, 2014.
123. Y. Kimura and H. Kimura, "Hydrogen sulfide protects neurons from oxidative stress", The FASEB Journal, vol. 18, no. 10, pp. 1165-1167, 2004.
124. 2S-releasing drugs as pharmaceuticals", Journal of Medicinal Chemistry, vol. 53, no. 17, pp. 6275-6286, 2010.
125. Y. Zhao, S. Bhushan, C. Yang et al., "Controllable hydrogen sulfide donors and their activity against myocardial ischemiareperfusion injury", ACS Chemical Biology, vol. 8, no. 6, pp. 1283-1290, 2013.
126. B. L. Predmore, K. Kondo, S. Bhushan et al., "The polysulfide diallyl trisulfide protects the ischemic myocardium by preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability", American Journal of Physiology-Heart and Circulatory Physiology, vol. 302, no. 11, pp. H2410-H2418, 2012.
127. C.-Y. Tsai, C.-C. Wang, T.-Y. Lai et al., "Antioxidant effects of diallyl trisulfide on high glucose-induced apoptosis are mediated by the PI3K/Akt-dependent activation of Nrf2 in cardiomyocytes", International Journal of Cardiology, vol. 168, no. 2, pp. 1286-1297, 2013.
128. Y. P. Lei, C. T. Liu, L. Y. Sheen, H. W. Chen, and C. K. Lii, "Diallyl disulfide and diallyl trisulfide protect endothelial nitric oxide synthase against damage by oxidized low-density lipoprotein", Molecular Nutrition and Food Research, vol. 54, supplement 1, pp. S42-S52, 2010.
129. C. C. Shin, P. K. Moore, and Y. Z. Zhu, "S-allylcysteine mediates cardioprotection in an acutemyocardial infarction rat model via a hydrogen sulfide-mediated pathway", The American Journal of Physiology-Heart and Circulatory Physiology, vol. 293, no. 5, pp. H2693-H2701, 2007.
130. Q. Wang, H.-R. Liu, Q. Mu, P. Rose, and Y. Z. Zhu, "S-propargylcysteine protects both adult rat hearts and neonatal cardiomyocytes from ischemia/hypoxia injury: the contribution of the hydrogen sulfide-mediated pathway", Journal of Cardiovascular Pharmacology, vol. 54, no. 2, pp. 139-146, 2009.